Alpha Cognition Inc. Common Stock

ZUNVEYL’s Alzheimer’s differentiation must be strong enough for long-term-care physicians, consultant pharmacists, LTC pharmacies, and Medicare payors to change prescribing behavior away from entrenched AChEIs. If this behavioral switch happens, small-account concentration can turn into recurring prescription revenue; if not, ZUNVEYL remains a costly launch with limited uptake.

The patented ZUNVEYL product must preserve premium net pricing and reliable commercial supply, because the launch model depends on high contribution per prescription rather than mass-market primary-care volume. High gross profit can fund commercialization; if rebates, access concessions, returns, or supply issues eat the economics, revenue growth will not translate into value.

The account-based LTC sales model must show operating leverage as adoption grows; if ZUNVEYL requires a much broader or slower commercial build, the economics become launch-spend intensive. Operating leverage is what turns a successful product into per-share value; without it, revenue growth may simply fund larger losses and future dilution.

Management must keep capital focused on ZUNVEYL commercialization and defer discretionary pipeline spending until the launch proves itself, because the company is still dependent on external capital if burn remains high. Capital discipline protects existing owners from dilution; loss of discipline shifts upside from product success to future financiers.

Non-core geography and pipeline optionality should be funded through partners, milestones, royalties, or non-dilutive sources rather than by redirecting launch capital away from ZUNVEYL. Partner-funded optionality can add upside without impairing the core launch; internally funded optionality before commercial proof increases dilution and execution risk.